Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
Complete Title: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Trial Phase: II
Investigator: Petros Grivas
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.
Keywords:
- Transitional Cell Carcinoma (TCC)
- Neoplasms, Glandular and Epithelial
- Urothelial Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Petros Grivas
RG1003350
NCT03547973
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Transitional Cell Carcinoma (TCC)
Neoplasms, Glandular and Epithelial
Urothelial Cancer